Product Images Galantamine
View Photos of Packaging, Labels & Appearance
- Figure 1: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 21 Weeks (5 Months) of Treatment - galantamine fig1
- Figure 10: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 13 Weeks of Treatment - galantamine fig10
- Figure 11: Cumulative Percentage of Patients Completing 13 Weeks of Double-Blind Treatment With Specified Changes from Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 90%, 24 to 32 mg/day 67%. - galantamine fig11
- FIGURE 12 - galantamine fig12
- Figure 2: Cumulative Percentage of Patients Completing 21 Weeks of Double-Blind Treatment With Specified Changes From Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 84%, 8 mg/day 77%, 16 mg/day 78% and 24 mg/day 78%. - galantamine fig2
- Figure 3: Distribution of CIBIC-plus Ratings at Week 21 - galantamine fig3
- Figure 4: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment - galantamine fig4
- FIGURE 5 - galantamine fig5
- Figure 6: Distribution of CIBIC-plus Ratings at Week 26 - galantamine fig6
- Figure 7: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment - galantamine fig7
- Figure 8: Cumulative Percentage of Patients Completing 26 Weeks of Double-Blind Treatment With Specified Changes From Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 87%, 24 mg/day 80%, and 32 mg/day 75%. - galantamine fig8
- Figure 9: Distribution of CIBIC-plus Rating at Week 26 - galantamine fig9
- Chemical Structure - galantamine str
- Label - lbl713352766
Product Label Images
The following 14 images provide visual information about the product associated with Galantamine NDC 71335-2766 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 21 Weeks (5 Months) of Treatment - galantamine fig1
Figure 10: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 13 Weeks of Treatment - galantamine fig10
Figure 11: Cumulative Percentage of Patients Completing 13 Weeks of Double-Blind Treatment With Specified Changes from Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 90%, 24 to 32 mg/day 67%. - galantamine fig11
FIGURE 12 - galantamine fig12
This text appears to be a list of responses on a scale of improvement, from "Markedly Improved" to "Markedly Worse", possibly related to a rating scale called CIBIC-plus. The information also includes a name "T Peosko", numbers, and some symbols like "@".*
Figure 2: Cumulative Percentage of Patients Completing 21 Weeks of Double-Blind Treatment With Specified Changes From Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 84%, 8 mg/day 77%, 16 mg/day 78% and 24 mg/day 78%. - galantamine fig2
Figure 3: Distribution of CIBIC-plus Ratings at Week 21 - galantamine fig3
This text provides dosage information for Placebo, with different dosages listed in milligrams per day. It also includes a scale to evaluate the level of improvement or change in a medical condition using different categories of improvement/worsening for the CIBIC-plus rating.*
Figure 4: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment - galantamine fig4
FIGURE 5 - galantamine fig5
Cumulative Percentage of Patients showing various changes in ADAS-cog score based on the points assigned. The data includes the number of patients at different point intervals and the corresponding changes from baseline. The information is presented in a tabular format, detailing the distribution of patients based on their score changes.*
Figure 6: Distribution of CIBIC-plus Ratings at Week 26 - galantamine fig6
This text provides information on the percentage of patients in different age groups and dosage levels experiencing varying degrees of improvement based on the CIBIC-plus Rating scale. The data includes the number of patients aged 60+ and the dosage received, with categories indicating different levels of improvement or worsening. It appears to be related to a clinical evaluation or research study but may require further context for a complete understanding.*
Figure 7: Time-Course of the Change From Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment - galantamine fig7
Figure 8: Cumulative Percentage of Patients Completing 26 Weeks of Double-Blind Treatment With Specified Changes From Baseline in ADAS-cog Scores. The Percentages of Randomized Patients Who Completed the Study Were: Placebo 87%, 24 mg/day 80%, and 32 mg/day 75%. - galantamine fig8
This text provides information on the Cumulative Percentage of Patients based on their ADAS-cog Change From Baseline score. It compares the results for patients taking placebo at two different doses (24 my/day and 32 my/day) over a span of 10 points, ranging from -5 to 15.*
Figure 9: Distribution of CIBIC-plus Rating at Week 26 - galantamine fig9
This text provides information about the percentage of patients with different levels of improvement in a study. It includes categories such as "Markedly improved," "Moderately improved," "Minimally improved," "No change," "Minimally worse," "Moderately worse," and "Markedly worse" based on their CIBIC-plus Rating. The percentages are displayed for three groups receiving different treatments. The treatment details include "Placebo" and different dosages taken over 24 months/day.*
Chemical Structure - galantamine str
Label - lbl713352766
This text provides information about Galantamine Hydrobromide tablets that are equivalent to 4 mg of galantamine base. It includes details of the dosage, storage instructions, and manufacturer information. The tablets are film-coated and come in a package of 60 tablets. The package insert can be accessed via a QR code on the box. The product is manufactured by Aurobindo Pharma and repackaged by Bryant Ranch Prepack, Inc.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
